205 related articles for article (PubMed ID: 2113808)
41. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centres with aminoglycoside usage.
Muscato JJ; Wilbur DW; Stout JJ; Fahrlender RA
J Antimicrob Chemother; 1991 May; 27 Suppl C():1-7. PubMed ID: 1906860
[TBL] [Abstract][Full Text] [Related]
42. Epidemiology of resistance to netilmicin and other aminoglycosides.
Toscano MA; Russo G; Nicoletti G; Stefani S; Geraci C; Alessandria E
Chemioterapia; 1986 Jun; 5(3):191-5. PubMed ID: 3719853
[TBL] [Abstract][Full Text] [Related]
43. Sensitivity of gram-negative bacteria to six aminoglycoside antibiotics.
Eyckmans L; Beert J
Infection; 1977; 5(1):9-12. PubMed ID: 404254
[TBL] [Abstract][Full Text] [Related]
44. Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin.
Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE; Packer RR
Antimicrob Agents Chemother; 1980 Aug; 18(2):338-45. PubMed ID: 7447410
[TBL] [Abstract][Full Text] [Related]
45. [In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli].
Lee J; Kim CK; Roh KH; Lee H; Yum JH; Yong D; Lee K; Chong Y
Korean J Lab Med; 2007 Aug; 27(4):292-7. PubMed ID: 18094591
[TBL] [Abstract][Full Text] [Related]
46. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
Gerding DN; Larson TA
Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
[TBL] [Abstract][Full Text] [Related]
47. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
Noone P
Drugs; 1984 Jun; 27(6):548-78. PubMed ID: 6376062
[TBL] [Abstract][Full Text] [Related]
48. Pseudomonas aeruginosa resistant to aminoglycosides: an assessment of the currently used methods of disk diffusion and dilution susceptibility.
Ismaeel NA
Microbios; 1991; 66(268-269):197-204. PubMed ID: 1907714
[TBL] [Abstract][Full Text] [Related]
49. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
Moellering RC; Wennersten C; Kunz LJ; Poitras JW
Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
[TBL] [Abstract][Full Text] [Related]
50. Activity of netilmicin compared with those of gentamicin and tobramycin against enterobacteria and Pseudomonas aeruginosa.
Chadwick P; Salmon S; Taylor B
Antimicrob Agents Chemother; 1977 Sep; 12(3):301-7. PubMed ID: 410361
[TBL] [Abstract][Full Text] [Related]
51. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F
J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
[TBL] [Abstract][Full Text] [Related]
52. [Current status of aminoglycoside resistance in hospital Enterobacteriaceae].
Ronco E; Migueres ML; Vacheron F; Guenounou M
Pathol Biol (Paris); 1988 May; 36(5):430-4. PubMed ID: 3043339
[TBL] [Abstract][Full Text] [Related]
53. In vitro interaction between cefotetan and aminoglycosides on Staphylococcus aureus and coagulase negative staphylococci, both methicillin-susceptible and -resistant.
Stefani S; Debbia E; Schito GC; Nicoletti G
Chemioterapia; 1988 Jun; 7(3):151-5. PubMed ID: 3168069
[TBL] [Abstract][Full Text] [Related]
54. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
Duncan IB; Skulnick M; Marshall PW
J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
[TBL] [Abstract][Full Text] [Related]
55. Gentamicin and tobramycin--an in vitro comparison using 1400 clinical isolates.
Forgan-Smith WR; Andrew JH; McSweeney RJ
Pathology; 1976 Jul; 8(3):195-9. PubMed ID: 826868
[TBL] [Abstract][Full Text] [Related]
56. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
Reyonolds AV; Hamilton-Miller JM; Brumfitt W
J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
[TBL] [Abstract][Full Text] [Related]
57. In vitro activity of netilmicin against clinical isolates of methicillin resistant and susceptible Staphylococcus aureus.
Manoharan A; Lalitha MK; Jesudason MV
Natl Med J India; 1997; 10(2):61-2. PubMed ID: 9153980
[TBL] [Abstract][Full Text] [Related]
58. In-vitro efficacy of cefotiam in combination with four aminoglycosides on staphylococci and Gram-negative bacteria.
Daschner FD; Steffens A; Schneider H
J Antimicrob Chemother; 1981 Sep; 8(3):239-41. PubMed ID: 6270053
[No Abstract] [Full Text] [Related]
59. In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.
Liu JY; Wang FD; Ho MW; Lee CH; Liu JW; Wang JT; Sheng WH; Hseuh PR; Chang SC
J Microbiol Immunol Infect; 2016 Dec; 49(6):918-923. PubMed ID: 26364729
[TBL] [Abstract][Full Text] [Related]
60. Investigation of isepamicin in vitro efficiency in Gram negative bacteria efficacy of isepamicin.
Yeliz TC; Ali HB; Sarah AF; Sreylis N; Kubra HU; Asuman B
Indian J Med Microbiol; 2021 Jan; 39(1):59-62. PubMed ID: 33610258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
